CN102481317B - 活性炭对达比加群酯过量给药的紧急干预 - Google Patents

活性炭对达比加群酯过量给药的紧急干预 Download PDF

Info

Publication number
CN102481317B
CN102481317B CN201080037665.XA CN201080037665A CN102481317B CN 102481317 B CN102481317 B CN 102481317B CN 201080037665 A CN201080037665 A CN 201080037665A CN 102481317 B CN102481317 B CN 102481317B
Authority
CN
China
Prior art keywords
dabigatran etexilate
dabigatran
charcoal
suspension
overdosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080037665.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102481317A (zh
Inventor
J.范里恩
A.克莱门斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN102481317A publication Critical patent/CN102481317A/zh
Application granted granted Critical
Publication of CN102481317B publication Critical patent/CN102481317B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201080037665.XA 2009-08-24 2010-08-23 活性炭对达比加群酯过量给药的紧急干预 Expired - Fee Related CN102481317B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23632109P 2009-08-24 2009-08-24
US61/236,321 2009-08-24
PCT/EP2010/062229 WO2011023653A1 (en) 2009-08-24 2010-08-23 Emergency interventions of active charcoal with dabigatran etexilate overdosing

Publications (2)

Publication Number Publication Date
CN102481317A CN102481317A (zh) 2012-05-30
CN102481317B true CN102481317B (zh) 2014-09-03

Family

ID=42740360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080037665.XA Expired - Fee Related CN102481317B (zh) 2009-08-24 2010-08-23 活性炭对达比加群酯过量给药的紧急干预

Country Status (20)

Country Link
US (2) US20110206656A1 (enExample)
EP (1) EP2470187B1 (enExample)
JP (1) JP2013502449A (enExample)
KR (1) KR20120050457A (enExample)
CN (1) CN102481317B (enExample)
AR (1) AR077909A1 (enExample)
AU (1) AU2010288601A1 (enExample)
BR (1) BR112012004169A2 (enExample)
CA (1) CA2767966A1 (enExample)
CL (1) CL2012000488A1 (enExample)
DK (1) DK2470187T3 (enExample)
EA (1) EA201200319A1 (enExample)
ES (1) ES2436076T3 (enExample)
IL (1) IL216968A0 (enExample)
MX (1) MX2012001767A (enExample)
NZ (1) NZ597359A (enExample)
PH (1) PH12012500388A1 (enExample)
PL (1) PL2470187T3 (enExample)
TW (1) TW201124143A (enExample)
WO (1) WO2011023653A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
AP2013007046A0 (en) * 2011-03-30 2013-08-31 Boehringer Ingelheim Int Anticoagulant antidotes
GB201120693D0 (en) * 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN114452839B (zh) * 2022-02-10 2023-04-21 中南大学湘雅医院 一种抗凝抗栓血液净化膜及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277820A (en) * 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DK1485094T4 (da) 2002-03-07 2020-06-22 Boehringer Ingelheim Int Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277820A (en) * 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Emergency medicine: activated charcoal-the first-line agent in cases of overdose;GUSS D A，等;《WESTERN JOURNAL OF MEDICINE,AFFILIATED CLINICAL INVESTIGATION SOCIETIES》;19890701;第151卷(第1期);63 *
G.M. COOPER,等.A randomized clinical trial of activated charcoal for the routine management of oral drug overdose.《Q J MED》.2005,第98卷 *
How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases?;Chiyo I. Kawasaki，等;《clinicaltoxicology》;20051231;第43卷(第2期);95–99 *
Treatment of quinine overdosage with repeated oral charcoal;L. F. PRESCOTT,等;《BRITISH JOURNAL OF CLINICAL PHARMACOLOGY》;19890101;第27卷(第1期);95-97 *
Ximelagatran for stroke prevention in atrial fibrillation;Christopher j boos,等;《Expert Rev. Cardiovasc. Ther.》;20051231;第3卷(第4期);551-563 *

Also Published As

Publication number Publication date
IL216968A0 (en) 2012-02-29
EP2470187A1 (en) 2012-07-04
CL2012000488A1 (es) 2012-08-31
AR077909A1 (es) 2011-09-28
CN102481317A (zh) 2012-05-30
PH12012500388A1 (en) 2012-10-22
CA2767966A1 (en) 2011-03-03
KR20120050457A (ko) 2012-05-18
ES2436076T3 (es) 2013-12-26
BR112012004169A2 (pt) 2016-03-29
EA201200319A1 (ru) 2012-09-28
DK2470187T3 (da) 2013-10-28
TW201124143A (en) 2011-07-16
PL2470187T3 (pl) 2014-01-31
AU2010288601A1 (en) 2012-02-02
US20110206656A1 (en) 2011-08-25
JP2013502449A (ja) 2013-01-24
EP2470187B1 (en) 2013-08-21
US20130302311A1 (en) 2013-11-14
MX2012001767A (es) 2012-02-29
WO2011023653A1 (en) 2011-03-03
NZ597359A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
AU2009228795B2 (en) Process for preparing orally administered dabigatran formulations
CN100528157C (zh) 3-[(2-{[4-(己氧羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯及其盐的口服施用的投药剂型
US9089488B2 (en) Method for manufacturing medicinal compounds containing dabigatran
CN102123707A (zh) 用于经皮介入心导管插入术的达比加群
CN102481317B (zh) 活性炭对达比加群酯过量给药的紧急干预
WO2001076635A1 (en) Preparations for preventing bile acid diarrhea
CN104523654A (zh) 右兰索拉唑缓释胶囊及其制备方法
CN1956707B (zh) 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型
KR20110102339A (ko) 고정용량 복합제용 탐술로신 펠렛
BRPI0720958A2 (pt) Omposição de duloxetina
JP2006521300A (ja) 活性物質として白金錯体を含有する医薬組成物およびその製造方法
CN101632668A (zh) 口服药物组合物
CN109106687A (zh) 一种匹多莫德干混悬剂及其制备方法
HK1154499A (en) Dabigatran for percutaneous interventional cardiac catheterisation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140903

Termination date: 20160823